Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis
<p style="text-align:justify;"> The loss of muscle function seen in myasthenia gravis and in the animal model of the disease, experimental autoimmune myasthenia gravis (EAMG) is in part due to the activation of complement by anti-acetylcholine receptor (AChR) antibodies at the motor...
| Main Authors: | , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Elsevier
1997
|
| _version_ | 1797095355701002240 |
|---|---|
| author | Piddlesden, S Jiang, S Levin, J Vincent, A Morgan, B |
| author_facet | Piddlesden, S Jiang, S Levin, J Vincent, A Morgan, B |
| author_sort | Piddlesden, S |
| collection | OXFORD |
| description | <p style="text-align:justify;"> The loss of muscle function seen in myasthenia gravis and in the animal model of the disease, experimental autoimmune myasthenia gravis (EAMG) is in part due to the activation of complement by anti-acetylcholine receptor (AChR) antibodies at the motor end-plate. In this study we describe the effects of a soluble recombinant form of human complement receptor 1 (sCR1) on the development of clinical disease and receptor loss in EAMG induced passively by administration of anti-AChR antibodies. Daily intraperitoneal injection of sCR1 significantly reduced the weight loss and severity of clinical symptoms seen and allowed treated animals to recover normal muscle function. These data suggest that sCR1 could provide a useful additional therapeutic agent in myasthenia. </p> |
| first_indexed | 2024-03-07T04:26:43Z |
| format | Journal article |
| id | oxford-uuid:cce49dea-7730-43d7-94f3-8c7061a5ad9e |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T04:26:43Z |
| publishDate | 1997 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:cce49dea-7730-43d7-94f3-8c7061a5ad9e2022-03-27T07:24:56ZSoluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravisJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:cce49dea-7730-43d7-94f3-8c7061a5ad9eEnglishSymplectic Elements at OxfordElsevier1997Piddlesden, SJiang, SLevin, JVincent, AMorgan, B <p style="text-align:justify;"> The loss of muscle function seen in myasthenia gravis and in the animal model of the disease, experimental autoimmune myasthenia gravis (EAMG) is in part due to the activation of complement by anti-acetylcholine receptor (AChR) antibodies at the motor end-plate. In this study we describe the effects of a soluble recombinant form of human complement receptor 1 (sCR1) on the development of clinical disease and receptor loss in EAMG induced passively by administration of anti-AChR antibodies. Daily intraperitoneal injection of sCR1 significantly reduced the weight loss and severity of clinical symptoms seen and allowed treated animals to recover normal muscle function. These data suggest that sCR1 could provide a useful additional therapeutic agent in myasthenia. </p> |
| spellingShingle | Piddlesden, S Jiang, S Levin, J Vincent, A Morgan, B Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis |
| title | Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis |
| title_full | Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis |
| title_fullStr | Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis |
| title_full_unstemmed | Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis |
| title_short | Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis |
| title_sort | soluble complement receptor 1 scr1 protects against experimental autoimmune myasthenia gravis |
| work_keys_str_mv | AT piddlesdens solublecomplementreceptor1scr1protectsagainstexperimentalautoimmunemyastheniagravis AT jiangs solublecomplementreceptor1scr1protectsagainstexperimentalautoimmunemyastheniagravis AT levinj solublecomplementreceptor1scr1protectsagainstexperimentalautoimmunemyastheniagravis AT vincenta solublecomplementreceptor1scr1protectsagainstexperimentalautoimmunemyastheniagravis AT morganb solublecomplementreceptor1scr1protectsagainstexperimentalautoimmunemyastheniagravis |